AtaiBeckley (ATAI) Stock Price

AtaiBeckley Price

NASDAQ·CLOSED
7.35
​
Market closed

Revenue at AtaiBeckley has contracted by 27.1% per year over the past 5 years to 4.09 M USD. For AtaiBeckley, the net margin of -16,142.0% is down versus -823.6% a few years ago. The consensus 12-month price target for AtaiBeckley is 7.50 USD, about 2.0% above where the stock trades today. Of 21 analysts, 7 rate the stock a buy — an overall Hold consensus.

AtaiBeckley stock price

Access this data via the Eulerpool API

AtaiBeckley business model & stock analysis

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Berlin, Berlin and currently employs 119 full-time employees. The company went IPO on 2021-06-18. The firm engages in developing various treatments that focuses on various mental health disorders. The firm's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.

Frequently asked questions about AtaiBeckley

Analysts currently set an average price target of 7.69 USD for the AtaiBeckley stock (median: 7.50 USD), implying +4.6 % versus the latest price. The consensus is based on 21 analyst ratings.

21 analysts currently rate the AtaiBeckley stock: 7 recommend buying, 14 holding and 0 selling. For 2026, analysts expect AtaiBeckley to generate revenue of 2.16 M USD and earnings per share of -0.71 USD.

Converted at the current exchange rate, the AtaiBeckley share trades at 6.53 EUR (7.35 USD).

The AtaiBeckley share (ATAI) is listed on 5 stock exchanges, including: NASDAQ (ATAI), XETRA (9VC.DE), Frankfurt (9VC), München (9VC.MU), Düsseldorf (9VC.DU).

The expected revenue of AtaiBeckley is 2.16 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of AtaiBeckley is -156.90 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of AtaiBeckley is currently -10.40. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the AtaiBeckley stock.

The price-to-sales ratio (P/S) of AtaiBeckley is currently 755.71. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the AtaiBeckley stock.

The Eulerpool Quality Score for AtaiBeckley is 3/10.

The ISIN of AtaiBeckley is US04650F1012. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of AtaiBeckley is A3CSB4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of AtaiBeckley is ATAI. The ticker symbol is used to trade AtaiBeckley shares on the stock exchange.

Fair ValueTerminal
6.17 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
34,361.34 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website atai.life
Country
Currency
USD
Initial public offering
Jun 18, 2021
ISIN
US04650F1012
Cusip
N0731H103
Market capitalization
2.67 B USDMid Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
0.12
P/E ratio
P/Ee 2026
-10.40
P/Ee 2027
-10.61
P/Ee 2028
-9.43
P/Ee 2029
-11.98
P/Ee 2030
-34.13
P/Se
755.71
EV/EBIT
—
P/B Ratio
12.03
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-297.12 %
Gross Margin
75.25 %
EBIT Margin
-2,439.74 %
Net Margin
-16,142.01 %
EPS (Earnings Per Share)
-2.97 USD
Net Debt / EBIT
0.85
Debt/Equity
0.00
Last updated Oct 5, 2026, 5:33 PM

AtaiBeckley Peer Group

AtaiBeckley Ticker

DÜSSELDORF · 9VC.DUFRANKFURT · 9VCMUNICH · 9VC.MUNASDAQ · ATAIXETRA · 9VC.DE

All fundamentals and in-depth analysis of AtaiBeckley

Our stock analysis for AtaiBeckley stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AtaiBeckley. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.